Five-year risk of CIN 3+ to guide the management of women aged 21 to 24 years

Journal of Lower Genital Tract Disease

Volumn 17, Issue 5 SUPPL.1, 2013, Pages

  Katki, Hormuzd A ^a   Schiffman, Mark ^a   Castle, Philip E ^b   Fetterman, Barbara ^c   Poitras, Nancy E ^c   Lorey, Thomas ^c   Cheung, Li C ^d   Raine Bennett, Tina ^e   Gage, Julia C ^a   Kinney, Walter K ^f  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c Regional Laboratory   (United States)

^d INFORMATION MANAGEMENT SERVICES INC   (United States)

^e DIVISION OF RESEARCH   (United States)

^f KAISER PERMANENTE   (United States)

Author keywords

Cancer prevention; Cervical intraepithelial neoplasia (CIN); Human papillomavirus (HPV); Pap; Young adult

Indexed keywords

ADULT; ARTICLE; CANCER RISK; CANCER SCREENING; CERVICAL INTRAEPITHELIAL NEOPLASIA GRADE 3; FEMALE; FOLLOW UP; GROUPS BY AGE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; SQUAMOUS CELL; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

ADULT; CALIFORNIA; CERVICAL INTRAEPITHELIAL NEOPLASIA; COHORT STUDIES; FEMALE; HUMANS; MASS SCREENING; PAPILLOMAVIRUS INFECTIONS; RISK ASSESSMENT; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; VIROLOGY; YOUNG ADULT;

EID: 84876140888     PISSN: 10892591     EISSN: 15260976     Source Type: Journal    
DOI: 10.1097/LGT.0b013e3182854399     Document Type: Article

References (11)

1. Moscicki AB, Cox JT. Practice improvement in cervical screening and management (PICSM): symposium on management of cervical abnormalities in adolescents and young women. J Low Genit Tract Dis 2010;14: 73-80.
2. ArbynM, Kyrgiou M, Simoens C, Raifu AO, Koliopoulos G, Martin-Hirsch P, et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ 2008;337:a1284.
3. Khalid S, Dimitriou E, Conroy R, Paraskevaidis E, KyrgiouM,Harrity C, et al. The thickness and volume of LLETZ specimens can predict the relative risk of pregnancy-related morbidity. BJOG 2012;119: 685-91.
4. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain JM, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis 2012;16: 175-204.
5. Massad LS, Einstein M, Huh WK, Katki H, Kinney W, Schiffman M, et al. 2012 Updated Consensus Guidelines for the Management of Abnormal Cervical Cancer Screening Tests and Cancer Precursors. J Low Genit Tract Dis 2013;17:S1YS27.
6. Moore G, Fetterman B, Cox JT, Poitras N, Lorey T, Kinney W, et al. Lessons from practice: risk of CIN 3 or cancer associated with an LSIL or HPV-positive ASC-US screening result inwomen aged 21to24. J Low Genit Tract Dis 2010;14: 97-102.
7. Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol 2011;12: 663-72.
8. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002;287: 2114-9.
9. Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, et al. Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines. J Low Genit Tract Dis 2013;5:S28YS35.
10. Lawless JF. Statistical Models and Methods for Lifetime Data. 2nd ed. Hoboken, NJ: Wiley-Interscience; 2003.
11. Turnbull B. The empirical distribution function with arbitrarily grouped, censored and truncated data. J Roy Stat Soc B 1976;38: 290-5.